Evidence map›Paper›PMID 41362703›Full record

ArticleJTO clinical and research reports2025

Rapid-onset Severe Cytokine Release Syndrome With Marked Interleukin-6 Increase and Acute Liver Injury After the First Tarlatamab Dose in SCLC: Case Report.

Kento Takagi, Go Saito, Toshiaki Inazaki, Hikaru Shojima, Jun Miyakoshi, Akira Naito, Shun Sato, Takashi Shimazui, Haruka Anzai, Chiaki Imai and 1 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kento TakagiDepartment of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Go SaitoDepartment of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Toshiaki InazakiDepartment of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Hikaru ShojimaDepartment of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Jun MiyakoshiDepartment of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Akira NaitoDepartment of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Shun SatoDepartment of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Takashi ShimazuiDepartment of Emergency and Critical Care Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.
Haruka AnzaiDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Chiaki ImaiDivision of Pharmacy, Chiba University Hospital, Chiba University, Chiba, Japan.
Takuji SuzukiDepartment of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tarlatamab is a novel bispecific T-cell engager therapy with promising efficacy in patients with previously treated extensive-stage SCLC. Cytokine release syndrome (CRS) is the most common adverse event related to tarlatamab, although severe CRS remains rare, and grade 3 or higher adverse events have been reported to be less common with tarlatamab than with chemotherapy. Available clinical data on severe adverse events associated with tarlatamab remain limited. Herein, we report a case of a 55-year-old woman with extensive-stage-SCLC who was treated with tarlatamab. Severe CRS and liver injury rapidly developed in the patient after the first tarlatamab dose, which led to treatment discontinuation. This report also presents the temporal changes in serum interleukin-6 levels, highlighting its potential utility as a biomarker for the onset and severity of CRS.

Indexed as

Case reportCytokine release syndromeLiver injurySCLCTarlatamab

Identifiers

PMID41362703
PMCPMC12681894

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.